Date post: | 12-Jan-2016 |
Category: |
Documents |
Upload: | jason-kennedy |
View: | 219 times |
Download: | 0 times |
MRCPsych Training:Down’s Syndrome and Alzheimer’s
Disease
Dr Shelley Bevins, Clinical PsychologistLorna Rogers Community Nurse
Community Learning Disabilities Team, Plymouth Community Healthcare, CIC
Once you’ve met one person with dementia….you’ve met one person with
dementia” Tom Kitwood
This morning
• What we hope to cover:– What is dementia and why is it more
prevalent in people with Down’s syndrome?– Assessment of dementia (including a brief
introduction to neuropsychological assessment in people with LD)
– Supporting people with LD and dementia.– Case vignettes
What do you know about dementia?
• What are the symptoms?
• Who is at risk?
• Can it be treated?
• Can it be cured?
• Is there a test for it?
• How long does it last?
DSM-IV definition of dementia
• Diagnostic features include : memory impairment and at least one of the following: aphasia, apraxia, agnosia, disturbances in executive functioning.
• In addition, the cognitive impairments must be severe enough to cause impairment in social and occupational functioning.
• Importantly, the decline must represent a decline from a previously higher level of functioning.
• Finally, the diagnosis of dementia should NOT be made if the cognitive deficits occur exclusively during the course of a delirium.
What causes dementia?• Cerebral cortical degeneration:
AD, LBD, FTD (behavioural and language variants)• Subcortical degeneration:
PD, HD, CBD, PSP• Toxic/metabolic disorders:
Alcohol, Vitamin B12 deficiency• Cerebrovascular:
Multi-infarct dementia, Subcortical Ischemic Vascular Disease, CADISIL
• Infections/inflammation:CJD, MS, AIDS
• Neurological insult:Tumour, hydrocephalus, brain injury, dementia pugilistica, subdural haematoma.
Alzheimer’s type dementia
(50-70%)
Vascular
Dementia
(10-15%)
Lewy Body Dementia
(10%)
Fronto-temporal dementia
(9-12%)
Causes & Risk Factors of dementia
• Age • Gender (even when controlling for longevity).
Females increased AD likelihood, Males VD• Vascular risk factors (smoking, vascular disease,
diabetes etc), even in AD• Head Trauma• Education (and head size) ? Cognitive reserve• Family history • Apolipoprotein E (ApoE) statusMcCullagh et al., (2001)
Alzheimer’s Disease: Plaques and Tangles
• ? Cause or symptom
• Amyloid Plaques are deposits of beta-amyloid protein that build up in the spaces between nerve cells.
• Neurofibrillary Tangles are twisted fibres of tau protein that build up inside cells.
• Neocortical atrophy with neuronal loss
• Synaptic loss
• Neurochemical changes – cholinergic deficits to cortical and limbic regions.
Diagnostic Triangle
History (Medical, Personal)History (Medical, Personal)
PresentationPresentation Test ScoresTest Scores
Symptoms of Alzheimer’s Disease - ‘What to look out for’EARLY ‘STAGE’
Loss of short-term
memory
Loss of daily living skills
Loss of sociability
Loss of interest in favoured hobbies
Withdrawal of spontaneous communication
Disorientation / confusion
Increased wandering
Onset of seizures
MID ‘STAGE’
Language problems - naming objects,
maintaining conversation, understanding others.
Disorientation in time, place and person.
Confusion.
Loss of self-care / incontinence.
More severe changes in personality
and social behaviour.
Irrational fears.
Verbal / physical aggression.
LATE ‘STAGE’
Problems with walking/balance Seizure activity
Loss of eating/drinking/self-care skills Severe intellectual deterioration
Marked personality and mood changes Incontinence
Down’s Syndrome (DS)
• DS is the most common syndrome associated with learning disabilities (20%).
• 95% of DS cases are Trisomy 21, 5% caused by other abnormalities of chromosome 21 (translocation and mosaicism.)
• People with DS are at higher risk of Alzheimer’s Disease at an earlier age than the general population.
Down’s Syndrome & Dementia
• Increased life expectancy
• Link between chromosome 21 and amyloid production
• Average age of onset is 55 years. 9 years (on average) from diagnosis to death.
• Virtually all people with DS >40 years show characteristic brain changes of AD - although not all show clinical signs.
Comparative Rates of Dementia -Down’s syndrome, Learning disabilities, General Population
Cooper (reproduced in BPS/RCP Guidance 2009)
DSLD
GP
Why this risk?
• In DS, apoE4 protein (established risk factor) might interact with A deposit, promoting amyloid formation.
• This results in the development of plaques and tangles as seen in AD.
• This build up is thought to be due to the over expression of the A precursor gene on Chromosome 21.
Differential Diagnosis
If not dementia, what could it be??
• Thyroid Disease• Depression & grief reactions• Sensory Impairment• Tumours• Vitamin B12• Acute confusional state (delirium, constipation,
infections, sodium levels, lack of sleep)• Environmental changes• Medication Side Effects• Subdural haematomas• Stroke• Brain Injury• Cervical Spine Instability• Alcohol & drugs• Epilepsy in dementia
Neuropsychology and the Assessment and
Treatment of Dementia
What is clinical neuropsychology?
•The study of brain-behaviour relationships
•Neurologists - how the brain is functioning
•Neuropsychologists - how the person is functioning as a result of the brain changes.
Neuropsychological Assessment
Reasons for a neuropsychological assessment in learning disability work
• Baseline of functioning• Monitoring change over time• Differential and clinical diagnosis• Specificity of diagnosis (type of dementia)• Monitoring impact of medication• Cognitive strengths and weaknesses - capacity• Assessment of executive functioning• Intervention planning
Neuropsychological Assessment
Orientation
ADLs
Social skills
Ability to organise life
LanguageMemory
Praxis
Visuospatial skills
Executive functions
Neuropsychological assessment of dementia (non LD)
• Screening tools include:– AMTS, MMSE, ACE-R, CamCog, MEAMS, RBANs– NART / WTAR (premorbid functioning)
• Further Assessments may include– Estimates of premorbid level of functioning– Memory – Language – Executive functions – Attention & concentration– Visuospatial– IQ – Praxis
Neuropsychological Assessment of dementia (LD)
The Plymouth Psychology dementia screen• Review all file information• Individual testing
– Verbal comprehension (and general verbal ability level)– Tests of visual memory– Naming– Orientation – Tests of planning and problem solving (new)
• With an informed carer– Clinical interview– Checklist of memory, mood, daily living skills & behaviour
(DLD)– Life events scale – Depression scale, if relevant
BPVS
Crayton & OliverObject Memory
Dementia in Learning Disabilities (DLD)
• Formerly known as the DMR (Evenhuis et al., 2007). • 50 item informant questionnaire. • Eight sub-scales: short term memory, long term
memory, orientation (making up Sum of Cognitive Scores), speech, practical skills, mood, activity and interest and behavioural disturbance (making up Sum of Social Scores).
• Problems with poor inter-rater reliability• Cut off scores are available for probable dementia in
people with Down’s syndrome (separated into people with mild, moderate and severe LD)
Frequency of screening
• Under 30 years: screen once.
• 40-49 years: every 2 years.
• 50 + years: annually.
• On anti-dementia drugs: screen every 6 months for as long as required.
• For non-DS, people are screened as and when concerns arise and re-screened 6-12 months later.
104 people with DS on screening
programme register
5 with Dementia
92 no concerns
5 with concerns
being investigate
d
Age group
National rates (from BPS/MRCPsych)
Plymouth rates
30-39 Up to 2% 0
40-49 10-25% 2/31 (7%)
50-59 20-50% 1/18 (6%)
60+ 30-75% 2/4 (50%)
Group Activity
• Derek Video
Interventions
• ACIs (Anti-dementia medications)• Environmental modification• Memory boxes/books• Communication passports• Training and education for individual, friends,
carers and family• Individualised (person-centred) plans for
supporting the person with dementia.• Health Action Plans & Annual Health Checks
• Donepezil (Aricept)
• Rivastigmine
• Galantamine
• Memantine – partial NMDA antagonist
Acetyl cholinesterase inhibitors (AChIs)
Cholinergic hypothesis
• Levels of choline acetyltransferase activity reduces in AD, DLB and Parkinson’s dementia.
• There is a correlation of cholinergic deficit with degree of dementia and with pathological lesions (plaques)
• Acetylecholinesterase inhibitors prevent the breakdown of acetylcholine postsynaptically by deactivating AChE – thereby increasing ACh activity
Choline acetyltransferase
synthesises choline and acetyl-coenzyme
A into the neurotransmitter acetylcholine
Acetylcholinesterase (AChE) breaks
acetylcholine back into acetate and
choline
Efficacy of medications• NICE guidelines (2011) recommend for mild-
moderate AD.• Small treatment effects on RCT studies in general
population (Cochrane, 2009).• However, AD2000 (2004) study showed no benefit
from donepezil in a large RCT.– Cognition averaged 0.8 MMSE points better– Functional skills 1.0 BADLs point better– No significant benefits in terms of institutionalisation or
progression of disability– No difference in BPSD, carer distress, formal care costs,
unpaid caregiver time, adverse events or deaths• Conclusion: “Donepezil is not cost effective, with
benefits below minimally relevant thresholds. More effective treatments than Cholinesterase Inhibitors are needed for Alzheimer's disease.”
In people with Down’s syndrome:– Rivastigmine
• Less decline over 24 weeks in global functioning and adaptive behaviours (Prasher et al., 2005)
– Mixed results for Donepezil • No improvement in cognition (Prasher et al.,
2002) • Significant positive effects (Lott et al., 2002).• Initial improvement in global functioning and
adaptive behaviours. Follow up at 104 weeks significantly less ↓ in the treatment group (Prasher et al., 2003)
Recap
• Recap on dementia, particularly AD, including risk factors and neurodegenrative process
• Down’s syndrome and link between DS and AD
• Neuropsychological assessment of dementia in general and Down’s syndrome populations
• Interventions, including non-pharmacological interventions
• ACIs and evidence for their use in DS populations
Vignettes
Consider:• What might be happening for the
Service User?• What differential diagnoses might you
consider?• What assessments would you want to
undertake?• What would you do next?• Who else would you involve?